A product line not among Perrigo Company PLC’s sales growth drivers in nearly 30 years making it is the fulcrum for the firm’s outlook, not the first US OTC oral contraceptive it launched eight months ago.
Perrigo’s Formula To Drive Earnings Rebound Swings On Further Formula Business Recovery
“The infant formula business is recovering and we've taken actions to simplify and consumerize our business, but there's a lot more work to do,” says CEO Patrick Lockwood-Taylor as Perrigo’s announced latest results.
